Risks and benefits of espesolimab for the treatment of generalized pustular psoriasis
DOI:
https://doi.org/10.37711/rpcs.2023.5.1.407Keywords:
-Abstract
-
Downloads
References
Samotij D, Szczech J, Reich A. Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity. Int J Mol Sci [Internet]. 2021 [Consultado 2022 Jul 12]; 22(16):
doi: 10.3390/ijms22169048
Macaes CO, Lé AM, Torres T. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors. J Dermatolog Treat [Internet]. 2022 [Consultado 2022 Jul 12]; 33(7): 2911-2918. doi: 10.1080/09546634.2022.2089335
Hwang J, Rick J, Hsiao J, Shi VY. A review of IL-36: an emerging therapeutic target for inflammatory dermatoses. J Dermatolog Treat [Internet]. 2022 [Consultado 2022 Jul 12];
(6): 2711-2722. doi: 10.1080/09546634.2022.2067819
Baum P, Visvanathan S, Garcet S, Roy J, Schmid R, Bossert S, et al. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol [Internet]. 2022 [Consultado 2022 Jul 12]; 149(4): 1402-1412. doi: 10.1016/j.jaci.2021.09.035
Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Trial of Spesolimab for Generalized Pustular Psoriasis. N Engl J Med [Internet]. 2021 [Consultado 2022 Jul 12]; 385(26): 2431-2440. doi: 10.1056/NEJMoa2111563
Mrowietz U, Burden AD, Pinter A, Reich K, Schäkel K, Baum P, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb) [Internet]. 2021 [Consultado 2022 Jul 12]; 11(2): 571-585. doi: 10.1007/s13555-021-00504-0
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Iván David Lozada Martinez, Yessica Patricia Filorio Campos, Julio Cesar Arce, Rafael González
This work is licensed under a Creative Commons Attribution 4.0 International License.
